Fluxioxonil, trade name maxim, etc. are bactericides developed and produced by Novartis. Its mechanism is to inhibit the protein activating enzyme PK – Ⅲ (kinase – Ⅲ) with signal function in the process of osmotic induction transmission, resulting in the increase of the concentration of nonphosphorylated regulatory protein, Thus, the secretion of osmotic sensitive cell division agent activated protease is abnormal, which eventually leads to the death of bacteria. Because of its unique action mechanism, it has no cross resistance with existing fungicides. It is a kind of pyrrole fungicides with great development prospect.